Kite Pharma, a Gilead Company, has announced plans to evaluate Cellares’ automated manufacturing platform, the Cell Shuttle. The data generated in this proof-of-concept evaluation will be utilized to assess viability of the Cell Shuttle as a future manufacturing option for Kite.
While Kite Pharma has partnered with Cytiva to develop a new cell therapy manufacturing platform, which was rolled out last month, the Gilead Sciences subsidiary isn’t stopping there in its pursuit of expertise in the production of CAR-T medicines.
NORTHAMPTON, MA / ACCESSWIRE / June 19, 2024 / Gilead Sciences. Gilead and Kite Pharma teams raised Pride Month flags at our campuses last week symbolizing our united support for LGBTQ+ communities globally. Our commitment to inclusion and diversity is vital to our mission and will help us create a healthier world for all people.
With a former Kite Pharma leader at the helm, Santa Ana Bio has unveiled with $168 million and three precision medicine antibodies slated to enter the clinic next year.
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Cytiva, a biopharma research and manufacturing specialist, rolled out a new cell therapy manufacturing platform the company developed as part of a collaboration with Gilead Sciences’ Kite Pharma unit.
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
Kite, a Gilead Company, and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma programme. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program